Ready-to-use formulations

Polymer bioconjugation offers powerful strategies to extend half-life, improve stability, and enable encapsulation of therapeutic molecules. By conjugating polymers to proteins, peptides, or other actives, it is possible to enhance pharmacokinetics, reduce immunogenicity, and unlock new delivery pathways. ...

Custom polymers and lipids enable the creation of tailored delivery systems that meet the unique requirements of each therapeutic program. At Curapath, we support our partners with bespoke synthesis and design, offering flexibility in polymer architecture, lipid structures, functionalization, and scale. Th...

Ionizable lipids are key components in LNP formulations, enabling efficient RNA encapsulation and protection, while ensuring intracellular release through their pH-dependent charge switch. This unique property makes them essential for the safe and effective delivery of nucleic acid-based therapeutics. At ...

Shielding lipids play a crucial role in prolonging circulation time and enhancing the stability of LNPs by preventing opsonization and rapid clearance. Traditionally, PEG-lipids have been used for this purpose, but concerns around immunogenicity and tolerability have driven the search for better solutions....

Curapath offers a tiered suite of Formulation Development Packages to accelerate LNP and PNP development for nucleic acid and peptide delivery, with Essential, Advanced, and Expert options that increase in complexity, analytical depth, and formulation flexibility. These packages cover formulation‑screening...

Shielding lipids are key to keeping LNPs stable, long‑circulating, and efficient at delivering RNA or gene‑therapy payloads. As PEG‑based systems face growing concerns due to immunogenicity and accelerated clearance, new PEG‑free strategies are becoming essential for safer and more flexible nanoparticle de...

Biologic formulations often struggle with protein aggregation, immunogenicity, and limited shelf life, while polysorbates can degrade in aqueous environments and trigger PEG‑related reactions; PSar‑based solubilizing agents offer a next‑generation alternative that improves stability, enhances solubility at...

Curapath introduces a structured suite of Formulation Development Packages designed to streamline the creation and optimization of PLA/PLGA‑based nanoparticles for peptides and small molecules, offering three scalable levels of support: the Essential package focuses on rapid development of PLA/PLGA + API n...

Discover Curapath's cutting-edge offerings in our catalog. Explore our LNP and PNP components, as well as our polymer conjugates, all designed to advance drug delivery. Enhance your research and development with our high-quality products.Advanced Polymer & Lipid Solutions for Non-Viral Drug DeliveryPEG-free excipients, transfection reagents, and polymer platforms for next-generation therapeutics

Targeted LNP Shielding Lipids (PEG-Free) | CliCr® Conjugation | CurapathEngineered PEG-free polysarcosine lipids modified with CliCr® conjugation technology to enable precise ligand attachment and extrahepatic LNP targeting.Explore our Active Targeting Shielding Lipids catalog, a curated selection of PEG-free polysarcosine lipids engineered for precise ligand conjugation and extrahepatic LNP delivery.

From early formulation development to GMP manufacturing and aseptic Fill & Finish, supporting innovative therapeutics from preclinical to commercial supply.Explore Our Complete CDMO CapabilitiesExplore our CDMO Services overview, outlining our integrated approach to advanced lipid and polymer-based drug delivery, from early development to GMP manufacturing and aseptic Fill & Finish.

Curapath has launched a tiered suite of Formulation Development Packages to accelerate the design and optimization of Lipid Nanoparticle (LNP) and Polymer Nanoparticle (PNP) systems for nucleic acid and peptide delivery. These packages, Essential, Advanced, and Expert, are built to offer increasing levels of complexity, analytical depth, and formulation flexibility.

Curapath introduces a structured suite of Formulation Development Packages, designed to streamline the creation and optimization of PLA/PLGA-based nanoparticles for the encapsulation of peptides and small molecules.

Curapath and Certest have teamed up to develop next-generation Lipid Nanoparticle (LNP) formulations for nucleic acid-based therapeutics. This novel formulation combines Curapath's PEG-alternative shielding lipid with Certest's enhanced ionizable lipid, addressing challenges like immune-related side effects and reduced efficacy of PEG-based systems. This collaboration aims to improve stability, efficiency, and the versatility of payload delivery in advanced therapies.. Learn more about this cutting-edge combination of technologies by accessing the full document..

A biotech company developing a polymer-drug conjugate (PDC) for parenteral use needed a partner to support their transition to clinical trials. They required expertise in process development, scale-up, and GMP-compliant manufacturing. Curapath met these needs with a comprehensive approach, ensuring efficiency and quality at every stage. Learn more about how Curapath met the needs of this client by accessing the full document..

Our PolySarcosine based solution for biologics (Available for mAbs, recombinant vaccines, peptides, and hormones.) improves both Stability and Solubility outperforming current solutions like polysorbates without compromising safety.

Discover our cutting-edge capabilities for lipid nanoparticle characterization, alongside our meticulous in-process controls integrated into lipid nanoparticle formulations. Elevate your understanding of nanomedicine with our comprehensive insights. Download now to unlock the future of nanoparticle analysis.

LNP Formulation & Process Development Application Note! the sensitivity of LNPs for manufacturing and purification processes necessitates the development of a robust and scalable approach. This application note provides insight into Curapath's endeavor to achieve a GMP-compliant LNP formulation, demonstrating the critical path taken to ensure the production of clinically accepted drug products. Download now to understand the scalable manufacturing capabilities of Curapath.

Lipid Nanoparticle Formulation Characterization: Bridging the Gap from R&D to GMP Scale through Robust Analytical Excellence.

Polymer conjugation technologies enabling tailored solutions for drug delivery, biologics, and medical devices from development to GMP manufacturing.

Optimized Methods Towards Site-selective Cysteine Specific Bioconjugations for Therapeutic Delivery.

Polysarcosine (pSar)-a safer, more effective alternative to poly-ethylene glycol (PEG).

Development of a Highly Efficient, Biodegradable, Polymeric, Non-viral Vector (NVV) Platform for Nucleic Acid Delivery.

Development, Screening and Optimization of LNP Formulations using the NanoScaler.

Development of PEG-free Excipients for Drug Delivery.

Access Curapath’s PSar-based solutions to improve stability, solubility, and performance in advanced drug delivery systems.

Access Curapath’s Poly-L-Lysine-based solutions for enhanced delivery performance, functionalization, and advanced drug delivery applications.

Access Curapath’s Poly-L-Glutamic Acid-based solutions for improved solubility, stability, and performance in drug delivery systems.

Access Curapath’s Poly-L-Arginine-based solutions designed to enhance delivery performance and support advanced therapeutic applications.

Access Curapath’s Poly-L-Ornithine-based solutions for tailored drug delivery applications, enabling enhanced performance and formulation flexibility.

Explore LNP formulation, purification, and scalable manufacturing for mRNA delivery, from microfluidic mixing to GMP-ready production.

Implementation of IJM NanoScaler Pro: Automated screening system for lipid nanoparticle formulation.

Optimization, Scale-up, and GMP Manufacturing of a Polymer-Drug Conjugate for Parenteral Administration.

Certest and Curapath have joined forces to develop a novel LNP formulation leveraging the complementary Benefits of their proprietary excipients.

Scalable PLA/PLGA nanoparticle solutions for peptides and small molecules, with formulation, QC, and release studies for cost-effective drug delivery.

Discover our PSar-based solubilizing agent for improved biologic stability and solubility, offering a safe, scalable alternative to polysorbates.

Explore PEG-free shielding lipids that improve LNP stability, circulation, and targeting for more flexible and effective RNA delivery.

Explore how surface functionalization transforms LNPs into precise, receptor‑guided delivery systems for RNA therapeutics.

Explore next-generation lung-targeted LNPs with PEG-free PSar shielding and CliCr® conjugation for efficient, selective pulmonary delivery.

Discover CliCr®-modified shielding lipids for enhanced functionalization, particle stability, and targeted delivery from R&D to GMP-ready scale.

Discover Curapath's featured products catalog, a curated selection of advanced excipients and delivery components ready to accelerate your formulation programs.

Curapath offers high-quality LNP and PNP components, as well as polymer conjugates, designed to support advanced drug delivery research and development.

Curapath’s CDMO platform for advanced drug delivery, offering development, analytical services, GMP manufacturing, and sterile Fill & Finish.